BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 37752594)

  • 1. Meningiomas in patients with neurofibromatosis type 2 predominantly comprise 'immunogenic subtype' tumours characterised by macrophage infiltration.
    Teranishi Y; Miyawaki S; Nakatochi M; Okano A; Ohara K; Hongo H; Ishigami D; Sakai Y; Shimada D; Takayanagi S; Ikemura M; Komura D; Katoh H; Mitsui J; Morishita S; Ushiku T; Ishikawa S; Nakatomi H; Saito N
    Acta Neuropathol Commun; 2023 Sep; 11(1):156. PubMed ID: 37752594
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Validation of a scoring system to evaluate the risk of rapid growth of intracranial meningiomas in neurofibromatosis type 2 patients.
    Abi Jaoude S; Peyre M; Degos V; Goutagny S; Parfait B; Kalamarides M
    J Neurosurg; 2020 May; 134(5):1377-1385. PubMed ID: 32442973
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Allelic losses in neurofibromatosis 2-associated meningiomas.
    Lamszus K; Vahldiek F; Mautner VF; Schichor C; Tonn J; Stavrou D; Fillbrandt R; Westphal M; Kluwe L
    J Neuropathol Exp Neurol; 2000 Jun; 59(6):504-12. PubMed ID: 10850863
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term follow-up of 287 meningiomas in neurofibromatosis type 2 patients: clinical, radiological, and molecular features.
    Goutagny S; Bah AB; Henin D; Parfait B; Grayeli AB; Sterkers O; Kalamarides M
    Neuro Oncol; 2012 Aug; 14(8):1090-6. PubMed ID: 22711605
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Frequent NF2 gene transcript mutations in sporadic meningiomas and vestibular schwannomas.
    Lekanne Deprez RH; Bianchi AB; Groen NA; Seizinger BR; Hagemeijer A; van Drunen E; Bootsma D; Koper JW; Avezaat CJ; Kley N
    Am J Hum Genet; 1994 Jun; 54(6):1022-9. PubMed ID: 7911002
    [TBL] [Abstract][Full Text] [Related]  

  • 6. First insight into the somatic mutation burden of neurofibromatosis type 2-associated grade I and grade II meningiomas: a case report comprehensive genomic study of two cranial meningiomas with vastly different clinical presentation.
    Dewan R; Pemov A; Dutra AS; Pak ED; Edwards NA; Ray-Chaudhury A; Hansen NF; Chandrasekharappa SC; Mullikin JC; Asthagiri AR; ; Heiss JD; Stewart DR; Germanwala AV
    BMC Cancer; 2017 Feb; 17(1):127. PubMed ID: 28193203
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Population-based analysis of sporadic and type 2 neurofibromatosis-associated meningiomas and schwannomas.
    Antinheimo J; Sankila R; Carpén O; Pukkala E; Sainio M; Jääskeläinen J
    Neurology; 2000 Jan; 54(1):71-6. PubMed ID: 10636128
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical significance of NF2 alteration in grade I meningiomas revisited; prognostic impact integrated with extent of resection, tumour location, and Ki-67 index.
    Teranishi Y; Okano A; Miyawaki S; Ohara K; Ishigami D; Hongo H; Dofuku S; Takami H; Mitsui J; Ikemura M; Komura D; Katoh H; Ushiku T; Ishikawa S; Shin M; Nakatomi H; Saito N
    Acta Neuropathol Commun; 2022 May; 10(1):76. PubMed ID: 35570314
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A high-throughput kinome screen reveals serum/glucocorticoid-regulated kinase 1 as a therapeutic target for NF2-deficient meningiomas.
    Beauchamp RL; James MF; DeSouza PA; Wagh V; Zhao WN; Jordan JT; Stemmer-Rachamimov A; Plotkin SR; Gusella JF; Haggarty SJ; Ramesh V
    Oncotarget; 2015 Jul; 6(19):16981-97. PubMed ID: 26219339
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A role for the p53 pathway in the pathology of meningiomas with NF2 loss.
    Chang Z; Guo CL; Ahronowitz I; Stemmer-Rachamimov AO; MacCollin M; Nunes FP
    J Neurooncol; 2009 Feb; 91(3):265-70. PubMed ID: 18974932
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular genetic investigation of the neurofibromatosis type 2 tumor suppressor gene in sporadic meningioma.
    Harada T; Irving RM; Xuereb JH; Barton DE; Hardy DG; Moffat DA; Maher ER
    J Neurosurg; 1996 May; 84(5):847-51. PubMed ID: 8622160
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Somatic mutations in the neurofibromatosis type 2 gene in sporadic meningiomas.
    Papi L; De Vitis LR; Vitelli F; Ammannati F; Mennonna P; Montali E; Bigozzi U
    Hum Genet; 1995 Mar; 95(3):347-51. PubMed ID: 7868131
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Proliferation potential and histological features in neurofibromatosis 2-associated and sporadic meningiomas.
    Antinheimo J; Haapasalo H; Haltia M; Tatagiba M; Thomas S; Brandis A; Sainio M; Carpen O; Samii M; Jääskeläinen J
    J Neurosurg; 1997 Oct; 87(4):610-4. PubMed ID: 9322850
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular alterations in the neurofibromatosis type 2 gene and its protein rarely occurring in meningothelial meningiomas.
    Evans JJ; Jeun SS; Lee JH; Harwalkar JA; Shoshan Y; Cowell JK; Golubic M
    J Neurosurg; 2001 Jan; 94(1):111-7. PubMed ID: 11147878
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of bevacizumab on intracranial meningiomas in patients with neurofibromatosis type 2 - a retrospective case series.
    Alanin MC; Klausen C; Caye-Thomasen P; Thomsen C; Fugleholm K; Poulsgaard L; Lassen U; Mau-Sorensen M; Hofland KF
    Int J Neurosci; 2016 Nov; 126(11):1002-6. PubMed ID: 26365467
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cranial meningiomas in 411 neurofibromatosis type 2 (NF2) patients with proven gene mutations: clear positional effect of mutations, but absence of female severity effect on age at onset.
    Smith MJ; Higgs JE; Bowers NL; Halliday D; Paterson J; Gillespie J; Huson SM; Freeman SR; Lloyd S; Rutherford SA; King AT; Wallace AJ; Ramsden RT; Evans DG
    J Med Genet; 2011 Apr; 48(4):261-5. PubMed ID: 21278391
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Convexity Meningiomas in Patients with Neurofibromatosis Type 2: Long-Term Outcomes After Gamma Knife Radiosurgery.
    Ruiz-Garcia H; Trifiletti DM; Mohammed N; Hung YC; Xu Z; Chytka T; Liscak R; Tripathi M; Arsanious D; Cifarelli CP; Caceres MP; Mathieu D; Speckter H; Lekovic GP; Mehta GU; Sheehan JP
    World Neurosurg; 2021 Feb; 146():e678-e684. PubMed ID: 33152493
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Natural history of meningioma development in mice reveals: a synergy of Nf2 and p16(Ink4a) mutations.
    Kalamarides M; Stemmer-Rachamimov AO; Takahashi M; Han ZY; Chareyre F; Niwa-Kawakita M; Black PM; Carroll RS; Giovannini M
    Brain Pathol; 2008 Jan; 18(1):62-70. PubMed ID: 17924978
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cases of Mixed Schwannoma-Meningioma With and Without Neurofibromatosis 2 with Emphasis on Tumorigenesis.
    Rajeswarie RT; Mallik D; Rudrappa S; Gopal S
    Int J Surg Pathol; 2024 May; 32(3):511-514. PubMed ID: 37487199
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neurofibromatosis Type 2 (NF2) and the Implications for Vestibular Schwannoma and Meningioma Pathogenesis.
    Bachir S; Shah S; Shapiro S; Koehler A; Mahammedi A; Samy RN; Zuccarello M; Schorry E; Sengupta S
    Int J Mol Sci; 2021 Jan; 22(2):. PubMed ID: 33445724
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.